MedTrace Logo

A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies

NCT00953732 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2015-03-26

No results posted yet for this study

Summary

This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Lesion count

Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.

Sponsors & Collaborators

  • TKL Research, Inc.

    collaborator INDUSTRY

  • Peplin

    lead INDUSTRY

Principal Investigators

  • Eugene Bauer, MD · Chief Medical Officer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953732 on ClinicalTrials.gov